Clinical Trial Update: The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and tolerability of Alpha-1 Modified Process (MP) in individuals with Alpha-1-antitrypsin deficiency; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Alpha-1 Modified Process (MP)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-08-19